CLAIM CARD
The sole identified study investigating ACE inhibitor effects on immune and inflammatory pathways in the context of viral infection was an observational cohort using a transgenic mouse model. Animals were treated with lisinopril at a dose of 10 mg/kg per day for 21 days prior to intranasal inoculation with 10⁵ PFU of SARS-CoV-2 (Wuhan strain). The experimental design assessed viral load, ACE2 receptor expression in lung tissue, and markers of inflammatory response following infection. This preclinical model is relevant to the aging context because ACE2 expression changes with age and because the RAS axis is implicated in inflammaging. However, it is important to note that no direct human trials with aging-specific endpoints such as frailty, muscle function, or longevity were identified in the corpus. The study thus provides only indirect, mechanistic evidence regarding immune and inflammatory modulation by ACE inhibitors.
Evidence grade: exploratory
Contradiction status: none
Publication: 9ab2e887-2e5b-429a-8d89-fd6d7813a028
Provenance: Derivation Web chain
Citation Support
source_1Lin 2026source_2Din 2026source_3Spiegeleer 2025source_4Shen 2025source_5Bene 2025